428 Pharma

428 Pharma develops a formulation of the worlds first long-acting injectable (LAI) for prevention of relapse in MDD with a potential time to market in 2028.

428 Pharma pursues a PK-only pathway under FDA 505(b)(2) development with LOE until 2046.